KalVista Pharmaceuticals Inc (NASDAQ: KALV) on Tuesday, plunged -5.56% from the previous trading day, before settling in for the closing price of $11.87. Within the past 52 weeks, KALV’s price has moved between $7.21 and $16.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -24.26% over the last five years. The company achieved an average annual earnings per share of -1.94%. With a float of $29.84 million, this company’s outstanding shares have now reached $42.52 million.
The firm has a total of 150 workers. Let’s measure their productivity. In terms of profitability, gross margin is 29.77%, operating margin of -12899.42%, and the pretax margin is -11755.47%.
KalVista Pharmaceuticals Inc (KALV) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of KalVista Pharmaceuticals Inc is 30.95%, while institutional ownership is 83.91%. The most recent insider transaction that took place on Sep 09 ’24, was worth 89,622. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 7,352 shares at a rate of $12.19, taking the stock ownership to the 250,800 shares. Before that another transaction happened on Aug 23 ’24, when Company’s CHIEF MEDICAL OFFICER sold 2,135 for $12.40, making the entire transaction worth $26,474. This insider now owns 83,745 shares in total.
KalVista Pharmaceuticals Inc (KALV) Recent Fiscal highlights
As on 7/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.8 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.79) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.93 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.94% per share during the next fiscal year.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
KalVista Pharmaceuticals Inc (KALV) is currently performing well based on its current performance indicators. A quick ratio of 8.55 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.54, a number that is poised to hit -0.93 in the next quarter and is forecasted to reach -1.92 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
Analysing the last 5-days average volume posted by the [KalVista Pharmaceuticals Inc, KALV], we can find that recorded value of 0.31 million was lower than the volume posted last year of 0.5 million. As of the previous 9 days, the stock’s Stochastic %D was 7.88%. Additionally, its Average True Range was 0.72.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 20.48%, which indicates a significant increase from 0.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.98% in the past 14 days, which was higher than the 51.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.13, while its 200-day Moving Average is $12.30. Now, the first resistance to watch is $11.74. This is followed by the second major resistance level at $12.28. The third major resistance level sits at $12.55. If the price goes on to break the first support level at $10.93, it is likely to go to the next support level at $10.66. Now, if the price goes above the second support level, the third support stands at $10.12.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
Market capitalization of the company is 484.50 million based on 42,188K outstanding shares. Right now, sales total 0 K and income totals -126,640 K. The company made 0 K in profit during its latest quarter, and -40,440 K in sales during its previous quarter.
